-

Hundreds Of Patients Benefit From Access To Promising Treatments For Complex And Rare Disease Using AnovaOS™

  • Anova continues to provide a transformative approach for doctors to access promising new treatments for patients;
  • Physicians are using AnovaOSTM to request investigational new drugs for hundreds of patients who are benefitting across the U.S., Europe and Asia;
  • Biopharmaceutical companies are learning from these real-world cases to get treatments to market faster.

CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, continues to see the benefits of improved access to investigational treatment for patients with serious, complex and rare disease.

‘You can imagine the satisfaction that we feel, when otherwise I am certain we would be seeing progressive disease and deterioration,’ said Frank Senecal, MD and Founder of the South Sound Care Foundation (SSCF). Dr. Senecal was describing in the groups recently published Annual Report some of the early successes their program has had in finding new drugs to successfully treat their oncology patients. SSCF uses AnovaOS™ to manage access to investigational products for oncology patients at partner oncology practices in Washington state.

Biopharmaceutical companies face increased pressure to make investigational products available to patients who have serious and/or life-threatening disease. For biopharmaceutical companies the situation is complex. Manufacturers face conflicting desire to help patients in need while simultaneously maintaining their clinical development program without potentially being negatively impacted by adverse events that can occur in compassionate use cases. Biopharmaceutical companies must also consider cost to manufacture the investigational product, diversion of investigational product for use outside of approved clinical trials, or a lack of resources to review, approve and manage compassionate use requests.

Through physician practices, and networks like SSCF, Anova is helping biopharmaceutical companies deliver compassionate use programs that successfully collect quality data and support exploratory research across products and across multiple indications. The generation of data from real-world patients to support these pathways can help companies accelerate their development programs in a number of ways.

But for patients with serious and often life-threatening conditions, ‘such an opportunity provides hope for longer survival and control of the disease. It provides another path for hope,’ Senecal added.

In their recently published Annual Report, Dr Senecal describes one such case of a 39-year-old mother of two with a diagnosis of Glioblastoma (GBM) in 2019 – an aggressive form of brain cancer with 14-month median survival time – who accessed a personalised immunotherapy with the help of SSCF and the AnovaOS™ platform. After a number of treatments cycles and MRI scans, ‘for the first time, the patient has had a period of time where she is stable and hasn’t progressed. Her quality of life is improved which provides optimism and hope for their family.’

The SSCF continues to expand its program and the benefits being delivered for patients in need. With the support of AnovaOS™ the opportunity for physicians and their patients to access promising investigational treatments has dramatically improved. Anova is continuing to help clients and partners like SSCF build on these successes.

ENDS

About Anova
Anova Enterprises, Inc. (Anova) is accelerating clinical development with a technology platform (AnovaOS™) that streamlines access for those involved in research, accelerates throughput of new therapies, and provides a framework for collaboration, quality evidence generation and scientific insight.

www.anovaevidence.com
Twitter feed at @anovaevidence
Follow Anova at www.linkedin.com/company/anovaevidence

About South Sound CARE Foundation
The South Sound CARE Foundation (SSCF) brings the opportunity for life saving, cutting edge cancer clinical trials to patients in the South Sound. SSCFs caring medical professionals, local oncologists, and cancer advocates bring the best medical research possible right to Tacoma’s doorstep. Offering access to convenient, innovative and free clinical trials to those fighting cancer in the South Sound region, SSCF helps patients stay closer to home and their families.

www.southsoundcarefoundation.org/

Contacts

MEDIA CONTACT
Martin Walsh
martin@anovaevidence.com

CONTACT
Anova Enterprises, Inc.
One Arlington Executive Center,
3400 West Stonegate Boulevard, Suite 101,
Arlington Heights, IL60005
(224) 218-2408
info.us@anovaevidence.com

Anova Enterprises, Inc.

Details
Headquarters: Chicago, ILLINOIS
CEO: Christopher Beardmore
Employees: 21-50
Organization: PRI

Release Versions

Contacts

MEDIA CONTACT
Martin Walsh
martin@anovaevidence.com

CONTACT
Anova Enterprises, Inc.
One Arlington Executive Center,
3400 West Stonegate Boulevard, Suite 101,
Arlington Heights, IL60005
(224) 218-2408
info.us@anovaevidence.com

Social Media Profiles
More News From Anova Enterprises, Inc.

Anova Today Announced the Enrollment of 550+ Patients at 50+ Sites in Six Months for a Single Study

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, today announced the completion of enrollment of 550+ patients at 50+ sites for a single study in just six months, using it’s proprietary AnovaOS™ Platform. The program provided cancer doctors and patients with a promising treatment that was otherwise unavailable. The sponsor was provided with safety and efficacy data to support its drug development...

Anova Launches Global Clinical Registry to Accelerate Research and Access to Promising New Treatments

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, has announced the launch of a global clinical registry to accelerate the development of promising new treatments. The 21 CFR Part 11 compliant AnovaOS® global clinical registry provides a rich source of real-world evidence about research sites and patients, administrative efficiency in the conduct of research, a tool for post-market surveillance, an...

Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two patients in the highly anticipated study of DB107 for the treatment of brain tumors. The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed high-grade gliomas (HGG)...
Back to Newsroom